WO2023161828 - COMPOSITIONS OF EDTA HAVING ACTIVITY AGAINST PLANKTONIC AND BIOFILM CELLS OF CLINICALLY RELEVANT PATHOGENS
National phase entry:
Publication Number
WO/2023/161828
Publication Date
31.08.2023
International Application No.
PCT/IB2023/051639
International Filing Date
22.02.2023
Title **
[English]
COMPOSITIONS OF EDTA HAVING ACTIVITY AGAINST PLANKTONIC AND BIOFILM CELLS OF CLINICALLY RELEVANT PATHOGENS
[French]
COMPOSITIONS D'EDTA AYANT UNE ACTIVITÉ CONTRE DES CELLULES PLANCTONIQUES ET DE BIOFILM D'AGENTS PATHOGÈNES CLINIQUEMENT PERTINENTS
Applicants **
STERILECARE INC.
Inventors
MUELLER, Karen
Priority Data
63/312,516
22.02.2022
US
63/312,628
22.02.2022
US
63/396,052
08.08.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3903 | |
| EPO | Filing, Examination, Granting | 47016 | |
| Japan | Filing, Examination, Granting | 3632 | |
| South Korea | Filing, Examination, Granting | 5393 | |
| USA | Filing, Examination, Granting | 13940 |
Total:
73,884
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Described herein are compositions of EDTA having activity against planktonic and biofilm cells of clinically relevant pathogens. The compositions generally include EDTA and are capable of inhibiting the growth and proliferation of microbes. The compositions may also include additional active ingredients such as heparin, thrombolytic agents, taurolidine, chlorhexidine, ethanol, and combinations thereof.[French]
L'invention concerne des compositions d'EDTA ayant une activité contre des cellules planctoniques et de biofilm d'agents pathogènes cliniquement pertinents. Les compositions comprennent généralement de l'EDTA et sont capables d'inhiber la croissance et la prolifération de microbes. Les compositions peuvent également comprendre des ingrédients actifs supplémentaires tels que l'héparine, des agents thrombolytiques, de la taurolidine, de la chlorhexidine, de l'éthanol et des combinaisons de ceux-ci.